Because of the advent of novel medications with great efficacy, the oncology area is seeing tremendous expansion, which is fueling the growth of the oncology drug pipeline industry. For example, the United States Food and Drug Administration (US FDA) authorized 45 new molecular entities (NME) and biologic license applications (BLA) in 2015, with 16 of them being novel cancer medicines. As a result, the development of novel drugs is a crucial component driving the worldwide oncology drug pipeline analysis forward.
Cancer Prevention and Control through an Integrated Approach, which calls on governments and the World Health Organization (WHO) to take swift action to reduce cancer-related premature death. In the future term, such measures are projected to move the cancer drug pipeline market forward.
Read more @ https://bit.ly/34qufed
